DCT

1:26-cv-00736

Biogen Ma Inc v. Cipla Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00736, D. Del., 06/22/2026
  • Venue Allegations: Venue is based on Defendant Cipla USA, Inc. being a Delaware corporation that resides in the district and Defendant Cipla Ltd. being a foreign corporation subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Spinraza® (nusinersen) product constitutes an act of infringement of three U.S. patents covering methods of treating spinal muscular atrophy (SMA).
  • Technical Context: The technology involves an antisense oligonucleotide designed to modulate the splicing of the survival motor neuron 2 (SMN2) gene, thereby increasing the production of functional SMN protein to treat the underlying cause of SMA, a severe neurodegenerative genetic disorder.
  • Key Procedural History: This action was filed under the Hatch-Waxman Act, triggered by Defendants' submission of ANDA No. 219377 with a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic product. The asserted patents are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for Spinraza®.

Case Timeline

Date Event
2014-09-12 Earliest Priority Date for '559, '802, and '403 Patents
2018-03-27 U.S. Patent No. 9,926,559 Issues
2019-10-08 U.S. Patent No. 10,436,802 Issues
2024-06-18 U.S. Patent No. 12,013,403 Issues
2026-05-18 Cipla Ltd. sends Paragraph IV Notice Letter to Biogen
2026-05-19 Biogen receives Cipla's Notice Letter
2026-06-22 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,926,559 - "Compositions and methods for modulation of SMN2 splicing in a subject" (Issued Mar. 27, 2018)

The Invention Explained

  • Problem Addressed: Spinal Muscular Atrophy (SMA) is a neurodegenerative disorder caused by the loss of the survival motor neuron 1 (SMN1) gene (complaint does not specify; background from related patent: '802 Patent, col. 1:25-29). A nearly identical gene, SMN2, exists but primarily produces a truncated, non-functional protein because of a silent mutation that causes inefficient splicing and exclusion of a critical segment known as exon 7 '802 Patent, col. 1:30-44
  • The Patented Solution: The invention provides an antisense oligonucleotide (ASO) that binds to a specific site on the SMN2 pre-mRNA transcript (complaint does not specify; background from related patent: '802 Patent, col. 1:56-61). This binding event modulates the splicing process to promote the inclusion of exon 7, resulting in the production of full-length, functional SMN protein, thereby compensating for the missing protein from the SMN1 gene '802 Patent, col. 1:56-61
  • Technical Importance: This approach represents a method to treat the underlying genetic cause of SMA by leveraging the patient's own SMN2 gene, which is present in all individuals with SMA, to produce a functional therapeutic protein (complaint does not specify; background from related patent: '802 Patent, col. 33:25-39).

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶37
  • Claim 1 of the '559 Patent recites:
    • A method of treating a human subject having SMA;
    • The method comprises administering an ASO consisting of 18 linked nucleosides with the sequence of SEQ ID NO: 1;
    • The ASO has specific chemical modifications: each internucleoside linkage is a phosphorothioate, each nucleoside is a 2'-MOE nucleoside, and each cytosine is a 5-methyl cytosine;
    • The ASO is administered into the cerebrospinal fluid by bolus injection into the intrathecal space;
    • The administration is at a dose of 9.6, 10.3, 10.8, 11.3, or 12.0 milligrams Compl. ¶37
  • The complaint alleges infringement of one or more claims of the patent, including at least claim 1 Compl. ¶38

U.S. Patent No. 10,436,802 - "Methods for treating Spinal Muscular Atrophy" (Issued Oct. 8, 2019)

The Invention Explained

  • Problem Addressed: As with the '559 Patent, the invention addresses the deficiency of functional SMN protein in patients with SMA '802 Patent, col. 1:25-29 Beyond simply providing the therapeutic ASO, there is a need to establish an effective clinical dosing protocol to achieve and maintain therapeutic levels of the drug.
  • The Patented Solution: The patent claims a specific method of treatment using the same ASO described in the '559 Patent, but defines a specific multi-dose "loading" regimen. This involves administering three 12 mg doses over a defined period of approximately one month to initiate treatment '802 Patent, abstract '802 Patent, claim 1
  • Technical Importance: Defining a specific loading dose regimen is a critical step in drug development, aiming to rapidly achieve therapeutic concentrations of the drug in the target tissue to elicit a clinical response.

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶50
  • Claim 1 of the '802 Patent recites:
    • A method for treating a human subject with one or more symptoms of SMA;
    • The method uses the same 18-nucleoside ASO (SEQ ID NO: 1) with the same chemical modifications (phosphorothioate, 2'-MOE, 5-methyl cytosine) as claimed in the '559 Patent;
    • The ASO is administered via intrathecal injection;
    • The doses comprise a specific loading regimen: a first dose of 12 mg, a second dose of 12 mg administered 12-18 days after the first, and a third dose of 12 mg administered 25-35 days after the first Compl. ¶50
  • The complaint alleges infringement of one or more claims of the patent, including at least claim 1 Compl. ¶51

Multi-Patent Capsule

  • Patent Identification: U.S. Patent No. 12,013,403, "Compositions and methods for detection of SMN protein in a subject and treatment of a subject," Issued June 18, 2024 Compl. ¶27
  • Technology Synopsis: This patent claims a method of treating SMA in a human subject using the same ASO described in the '559 and '802 patents. The claims are directed to a more extended dosing schedule, comprising an initial loading phase followed by subsequent maintenance doses, for a total of six doses administered over approximately 300 days '403 Patent, claim 1
  • Asserted Claims: Independent claim 1 is asserted Compl. ¶63
  • Accused Features: The complaint alleges that the use of Cipla's Proposed ANDA Product, as directed by its proposed label, will infringe the claimed dosing regimen Compl. ¶65

III. The Accused Instrumentality

  • Product Identification: Cipla's Proposed ANDA Product, a generic version of Spinraza® (nusinersen) for intrathecal injection, identified as part of ANDA No. 219377 Compl. ¶1
  • Functionality and Market Context: The complaint alleges that the active ingredient in the accused product is nusinersen, the same ASO as in Biogen's Spinraza® Compl. ¶33 It is intended for the treatment of SMA Compl. ¶1 The complaint further alleges that the label for Cipla's product ("Cipla's Proposed Label") will be substantially identical to the Spinraza® label and will instruct healthcare professionals to administer the product in a manner that infringes the asserted patents Compl. ¶35 Compl. ¶39 As an ANDA product, it is positioned to be a direct, lower-cost competitor to Spinraza® upon receiving FDA approval Compl. ¶1

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

'559 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating a human subject having spinal muscular atrophy (SMA)... The proposed product is a generic version of Spinraza®, which is indicated for the treatment of SMA. ¶1 col. 33:25-39
...the method comprising administering to the human subject an antisense oligonucleotide consisting of 18 linked nucleosides, wherein the oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence SEQ ID NO: 1... The active ingredient is alleged to be nusinersen, an 18-nucleoside ASO with SEQ ID NO: 1. ¶33; ¶37 col. 34:50-54
...wherein each internucleoside linkage of the oligonucleotide is a phosphorothioate linkage, wherein each nucleoside of the oligonucleotide is a 2'-MOE nucleoside, and wherein each cytosine of the oligonucleotide is a 5-methyl cytosine... The active ingredient nusinersen is alleged to have the claimed chemical structure and modifications. ¶33; ¶37 col. 25:11-34
...wherein the antisense oligonucleotide is administered into the cerebrospinal fluid by bolus injection into the intrathecal space at a dose of 9.6, 10.3, 10.8, 11.3, or 12.0 milligrams of the antisense oligonucleotide. The proposed label is alleged to be substantially identical to the Spinraza® label and to instruct administration via intrathecal injection at an infringing dose. ¶35; ¶37; ¶39 col. 41:1-8

'802 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for treating a human subject having one or more symptoms associated with spinal muscular atrophy (SMA)... The proposed product is intended for treating SMA. ¶1 col. 1:10-14
...the method comprising administering by intrathecal injection doses of an antisense compound comprising an antisense oligonucleotide consisting of 18 linked nucleosides, wherein the oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence SEQ ID NO: 1... The active ingredient is alleged to be nusinersen, an 18-nucleoside ASO with SEQ ID NO: 1, administered via intrathecal injection. ¶33; ¶50 col. 1:56-61
...wherein each internucleoside linkage ... is a phosphorothioate linkage, wherein each nucleoside ... is a 2'-MOE nucleoside, and wherein each cytosine ... is a 5-methyl cytosine... The active ingredient nusinersen is alleged to have the claimed chemical structure and modifications. ¶33; ¶50 col. 25:11-34
...wherein the doses comprise: (i) a first dose of 12 mg...; (ii) a second dose of 12 mg ... 12-18 days after...; and (iii) a third dose of 12 mg ... 25-35 days after... The proposed label is alleged to be substantially identical to the Spinraza® label and to instruct administration according to the claimed loading dose regimen. ¶35; ¶50; ¶52 col. 43:42-51
  • Identified Points of Contention:
    • Scope Questions: A central question for infringement will be whether the final, FDA-approved label for Cipla's product requires the specific dosing regimens claimed in the '802 and '403 patents, or the specific doses in the '559 patent. The complaint's theory rests on the allegation that the proposed label will be "substantially identical" to the Spinraza® label Compl. ¶35 Any deviation in the final approved label that provides for non-infringing dosing alternatives would be a primary point of dispute.
    • Technical Questions: In this ANDA context, the technical dispute is more likely to arise in the context of validity rather than infringement. However, a question for the court may be whether the term "12 mg" as used in the claims can be read on a dose that is, for example, dose-equivalent but not an identical mass, should Cipla's product formulation differ in a relevant way.

V. Key Claim Terms for Construction

  • The Term: "treating"

  • Context and Importance: This term appears in the preamble of the asserted independent claims of all three patents. Its construction is fundamental to defining the scope of the claimed method. Practitioners may focus on this term because the threshold for what constitutes "treating" (e.g., stabilization, amelioration of one symptom, or a more significant clinical improvement) will be critical for both infringement and validity analyses.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The '802 Patent defines "amelioration" as "a lessening of severity of at least one indicator of a condition or disease" and notes it can include a "delay or slowing in the progression" '802 Patent, col. 20:59-65, which may support a broad definition of "treating."
    • Evidence for a Narrower Interpretation: The patent also provides detailed clinical trial data showing specific, significant improvements on the HFMSE scale '926,559 Patent, FIG. 1 '802 Patent, col. 65:1-68:41 A defendant may argue that "treating" should be limited to achieving a level of clinical improvement consistent with these examples.

  • The Term: "a dose of 12 mg" / "doses comprise"

  • Context and Importance: These phrases are at the heart of the infringement allegation for the specific dosing regimens claimed in the '802 and '403 patents. The dispute will likely focus on whether a physician following the instructions on the defendant's label is required to administer the claimed doses and schedules, or if the label merely suggests them as one possibility.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation (supporting infringement): The claims themselves are precise, reciting specific milligram amounts and timing intervals '802 Patent, claim 1 The patent's examples focus on this specific 12 mg dose, suggesting its centrality to the invention ('802 Patent, col. 67:1-68:41).
    • Evidence for a Narrower Interpretation (against infringement): The specification discusses the possibility of "adjusted doses" based on criteria like a patient's age or CSF volume, and mentions "equivalent doses" '802 Patent, col. 41:24-42:21 A defendant could use this language to argue that the 12 mg dose is merely exemplary and that a physician is free to use other, non-infringing doses, thereby potentially avoiding inducement.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges active inducement of infringement under 35 U.S.C. § 271(b). The factual basis is the allegation that Defendants' proposed product label will instruct and encourage healthcare professionals to administer the generic drug in accordance with the patented methods Compl. ¶45 Compl. ¶58 Compl. ¶71 It is also alleged that Defendants know the product is especially adapted for use in the patented methods and is not suitable for substantial noninfringing use, supporting contributory infringement under 35 U.S.C. § 271(c) Compl. ¶46 Compl. ¶59 Compl. ¶72
  • Willful Infringement: The complaint does not use the word "willful" but does lay the foundation for enhanced damages by pleading that Defendants had pre-suit knowledge of the asserted patents. This knowledge is alleged to come from the patents' listing in the FDA's Orange Book for Spinraza® and from Cipla's own notice letter referencing the patents Compl. ¶44 Compl. ¶57 Compl. ¶70 The prayer for relief asks for a finding that this is an "exceptional case" and an award of attorneys' fees Compl. ¶(f)

VII. Analyst's Conclusion: Key Questions for the Case

  • A primary issue will be one of validity: Will the Defendants succeed in proving by clear and convincing evidence that the asserted claims-particularly those directed to specific dosing regimens for an already-disclosed compound-are invalid, likely on grounds of obviousness in light of the state of the art for ASO-based therapies and SMA treatment at the time of invention?
  • A second core issue will be one of induced infringement by label: Assuming the claims are valid, does the language of the Defendants' final, FDA-approved product label direct, encourage, or require that medical professionals administer the generic product according to the specific doses and schedules recited in the patent claims, or does the label provide sufficient instruction for non-infringing uses?
  • A third question concerns the scope of the '559 patent claims: Does the claim language reciting a list of specific doses (e.g., "9.6, 10.3, 10.8, 11.3, or 12.0 milligrams") cover a product label that instructs a 12 mg dose but may also be interpreted to allow for dose adjustments by a physician, raising a question of whether such a label encourages a "substantial noninfringing use"?
Loading Complaint